Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded at Wall Street Zen

Posted by Geri Gentry on Aug 11th, 2026

Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) from a sell rating to a hold rating in a report released on Saturday.

Other equities research analysts also recently issued reports about the stock. Guggenheim cut their target price on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th. Cantor Fitzgerald raised their price target on shares of Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the company an “overweight” rating in a research note on Thursday, May 21st. Royal Bank Of Canada lifted their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Wells Fargo & Company decreased their price objective on Ultragenyx Pharmaceutical from $47.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, August 5th. Finally, Wedbush lowered their target price on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.82.

Read Our Latest Report on Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Trading Up 3.4%

Ultragenyx Pharmaceutical stock opened at $26.80 on Friday. The stock has a 50-day moving average price of $27.97 and a two-hundred day moving average price of $24.84. Ultragenyx Pharmaceutical has a 12 month low of $18.29 and a 12 month high of $39.89. The company has a market capitalization of $2.64 billion, a PE ratio of -4.59 and a beta of 0.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The company had revenue of $214.00 million for the quarter, compared to analysts’ expectations of $183.08 million. During the same period in the previous year, the business posted ($1.17) earnings per share. The business’s quarterly revenue was up 28.5% compared to the same quarter last year. As a group, analysts predict that Ultragenyx Pharmaceutical will post -4.42 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Howard Horn sold 4,653 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $23.77, for a total value of $110,601.81. Following the transaction, the chief financial officer owned 105,689 shares in the company, valued at approximately $2,512,227.53. The trade was a 4.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Shehnaaz Suliman sold 5,740 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $25.12, for a total transaction of $144,188.80. Following the completion of the sale, the director directly owned 27,951 shares in the company, valued at approximately $702,129.12. This represents a 17.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 14,292 shares of company stock worth $351,644 in the last 90 days. 5.20% of the stock is owned by company insiders.

Institutional Trading of Ultragenyx Pharmaceutical

A number of institutional investors have recently bought and sold shares of the company. Parallel Advisors LLC raised its position in shares of Ultragenyx Pharmaceutical by 778.4% in the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 1,440 shares in the last quarter. Leonteq Securities AG boosted its position in shares of Ultragenyx Pharmaceutical by 288.5% during the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,333 shares in the last quarter. Versant Capital Management Inc boosted its position in shares of Ultragenyx Pharmaceutical by 662.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,001 shares in the last quarter. Danske Bank A S acquired a new stake in Ultragenyx Pharmaceutical during the third quarter worth approximately $39,000. Finally, EverSource Wealth Advisors LLC grew its stake in Ultragenyx Pharmaceutical by 573.0% during the first quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 1,845 shares during the period. Institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

(Get Free Report)

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.